Novavax should be approved within a month.
AstraZeneca screwed up their trials, both in the US and the in UK. Their data is worthless. Further, studies have shown their vaccine is worthless against the South Africa variant. Back in July/August, I'd have told you that the AstraZeneca/Oxford vaccine was the most promising and likely to be the first out the door. Nobody knew they had done terribly sloppy trials and had an inferior product.
“Novavax should be approved within a month.”
They had long targeted April for authorization, but I have seen recent reports that they are now looking at May.
Reportedly, they have strong manufacturing capability lined up.
“Back in July/August, I’d have told you that the AstraZeneca/Oxford vaccine was the most promising”
FedGov made the same assessment last year - contracted for 400 million doses, the most of any candidate.
Reportedly, their US suppliers are already sitting on about 30 million finished doses, awaiting authorization, with strong production capacity standing by.
“Novavax should be approved within a month.”
Reuters reported on 12 March:
“Novavax Inc’s COVID-19 vaccine was 96 per cent effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom... 86 per cent effective in protecting against the more contagious virus variant first discovered and now prevalent in the United Kingdom (Kent variant).”